INTRODUCTION 1
The relative resistance of NK cells to transduction hampers the study of NK-cell biology and 2 the development of NK cell-based immunotherapy. VSV-G-LVs, classically used to generate 3 chimeric antigen receptor (CAR)-T cells,(1) do not efficiently transduce NK-cells. RD114-4 pseudotype viral vectors represent an attractive alternative since their entry receptor, the 5 sodium-dependent neutral amino acid transporters (ASCT2),(2, 3) is widely expressed in the 6 hematopoietic lineage.(4) However, despite encouraging initial report,(5) RD114-based viral 7 vectors only transduce NK-cells at low levels. Nevertheless, they recently enabled clinical 8 development of cord-blood derived CAR-NK-cells.(6) To fill the need for an efficient method 9 for transducing NK cells, we investigated alternative pseudotyping proteins. Since the Baboon 10 envelope pseudotyped lentiviral vector (BaEV-LV) binds ASCT1(7) in addition to ASCT2 for 11 viral entry, we assessed their efficacy to transduce NK-cells for therapeutic purposes. 12
13

RESULTS AND DISCUSSION 14
We first transduced NK cells expanded using the Amplification and Expansion System 15 (NKAES) and freshly isolated NK-cells (FI-NK) with an eGFP-encoding LV and observed 16 that in both cases, BaEV-LVs outperformed VSV-G-, MV-, and RD114-LVs ( Figure 1A , 17 83.4 % mean transduction rate vs 15.7%, 13.7% and 37.8% for NKAES, p <0.0001, and 18 23.0% vs 10.4%, 2.1% and 7.8% for FI-NK, p <0.0001, respectively). The mean transduction 19 rate with BaEV-LVs was higher than 60% for NKAES even at low MOI of 1, and ranged 20 from 12.4% at a MOI of 1 to a maximum of 27.2% at a MOI of 10 for FI-NK ( Figure 1B) . 21
The number of living cells in both NKAES and FI-NK was preserved after transduction with 22
BaEV-LVs ( Figure 1C ), suggesting that transduction did not affect viability or NK-cell 23 proliferation. Transgene expression persisted over time after transduction with BaEV-LVs, 24 although a decrease was observed from 70.6% to 61.4% in 14 days for NKAES (p=0.06). 25
Transduced FI-NK could be easily amplified after transduction (not shown). High 26 transduction rates were also observed after NK-cell expansion on K562-mbIL15-41BBL 27 feeder cells(9) or feeder-free NK MACS medium(15) ( Figure 1D ). 28
We then assessed whether NK-cell cytotoxic function was preserved after BaEV-LV 29 transduction and confirmed that the cytotoxicity of eGFP-transduced NKAES cells against 30 K562 cells was equivalent to non-transduced NKAES ( Figure 1E ). 31
RNAseq analyses of both FI-NK and NKAES showed that ASCT1 and ASCT2 mRNAs were 1 detected at significantly higher frequency in both IL-15-and IL-21-NKAES than in FI-NK 2 ( Figure 1F -G), which may explain the higher transduction rate of NKAES. These data were 3 confirmed by qPCR (not shown). Also, the expression of both BaEV receptors by NK cells 4 may explain the higher transduction efficacy of BaEV-LVs as compared to RD114 wich use 5 only one of those receptors. 6 CAR-expressing NK-cells represent one of the most relevant clinical applications of efficient 7 NK-cell transduction. We first tested a single 3 rd generation CAR construct recognizing CD22 8 ( Figure 2A ). We obtained a transduction rate of 44.2%±14.2% of NKAES sustaining high 9 level of CAR-expression ( Figure 2B -C), and we demonstrated that CD22-CAR-NK-cells 10 efficiently and specifically killed B-ALL RS4;11 target cells, which were resistant to 11 untransduced NKAES ( Figure 2D ). We could obtain 5x10 8 CAR-expressing cells from 5x10 5 12 transduced cells after an expansion of 14 days (not shown). Since transgene size affects 13 transduction efficacy,(16, 17) we also tested a dual CAR-expressing vector with two 14 independent chains recognizing CD19 and CD22. The length of the dual CAR-CD22/19 LV 15 had a significant impact on virus production since titers were under the detection limit (not 16 shown) and NK transduction was very low (<1%). We sorted and re-expanded these dual-17 CAR-transduced NK-cells for two weeks, to assess their cytotoxicity. Importantly, we showed 18 that these CAR-CD22/19-NKAES killed efficiently CD19 KO -CD22 KO -RS4;11 cells, which 19 suggest that this strategy could be efficient for preventing tumor evasion to CAR therapy(18, 20 19) ( Figure 2E ). 21
In this study we showed that BaEV-LV is an efficient and robust tool to transduce NK cells. 22
As a proof-of-concept, we generated large numbers of engineered CAR-NK-cells, which 23 induced specific killing of antigen-bearing cancer cells, even with a large dual CAR-LV 24 construct. This technique was robust and reproducible in different expansion systems, 25
including a feeder-cell-free system. The higher level of transduction could open up 26 possibilities for the use of this method to generate an immunotherapeutic product. The 27 prevalence of receptors, as seen by RNAseq, could explain the difference seen between the 28 transduction of activated and resting NK cells. The fact that activated NK cells express both 29 entry receptors at high level could also explain why this envelope protein is more efficient Measles virus (MV-LV) and BaEV envelope plasmids were used as previously described (7). 24
Titration was performed on HEK293T cells (ATCC) using serial virus dilutions.(7) 25
Viral transduction 26
NKAES were transduced after one week of expansion. A day before transduction, a 12-well 27 plate was coated with RetroNectin (Takara). The following day, concentrated vectors at 28 indicated multiplicity of infection (MOI), were added to coated plates for 4 hours at 37°C. 29
Then NK cells were seeded in these wells in IL-2-supplemented medium and protamine 30 sulfate (Pharmaceutical Partners of Canada Inc) (8 ug/mL). The plates were then centrifuged 31 at 1000g for 1 hour and incubated at 37°C overnight. The next day, IL-2-supplemented 32 medium was added to each well. Transduction was assessed on day 3 or day 5 after 1 transduction for NKAES and freshly isolated NK-cells (FI-NK), respectively. 
